uniQure Appoints SVP, Investor Relations And Communications
Gene therapy specialist uniQure N.V. has appointed Maria E. Cantor senior vice president, investor relations and communications. Cantor has over 20 years of communications experience in the biotech and healthcare industry, most recently at ARIAD Pharmaceuticals, where she was senior vice president, corporate affairs. Prior to this, she was senior director, corporate communications at Genzyme Inc., having previously held senior positions at the St. Elizabeth Medical Center in Boston, US, and at Optima Healthcare Inc.
You may also be interested in...
Combination of antibody therapy and Gilead's Veklury fails to show potential in patients with advanced disease.
Coronavirus Update: AstraZeneca’s Vaccine Trials Cleared To Restart In the US, J&J Prepares To Restart Its Vaccine Study
Two potential COVID-19 vaccine trials from AstraZeneca and Johnson & Johnson are set to resume in the US following temporary pauses due to safety concerns. Data from both could come later this year.
Gilead's remdesivir is first drug fully approved by FDA to treat COVID-19. Roche and Atea team up on an investigational direct acting antiviral while Moderna reaches the 30,000-patient enrollment target for its Phase III COVE study of the company's investigational mRNA vaccine.